SEC Form 4 · accession 0001209191-18-028490
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shao-Lee Lin
Officer — EVP, Head of R&D and CSO
Period of report
May 3, 2018
Accepted (ET)
May 7, 2018 · 8:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units (RSU)F2,F1,F3 | — | May 3, 2018 | A | 97,087 | A | — | — | Ordinary Shares | 97,087 | 97,087 | D |
Explanation of responses
- F1Each RSU represents a contingent right to receive one ordinary share of the Issuer.
- F2The RSU's were approved by the Issuer's Compensation Committee on January 5, 2018, subject to shareholder approval of certain amendments to the Issuer's 2014 Equity Incentive Plan (the "Plan") under which the RSU's were granted. The Issuer's shareholders approved the amendments to the Plan on May 3, 2018.
- F3The RSU's vest 1/3rd annually on each anniversary of January 5, 2018.